- For Print
- July 25, 2022
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that lecanemab, an anti-amyloid-β protofibril antibody being developed by Eisai, has no connection regarding an article published in the US scientific journal Science on July 22, 2022.
This article reported that a research paper on Aβ*56, a type of Aβ oligomer, is under investigation for its credibility, but this case has no relation to lecanemab.
Lecanemab showed a correlation between Aβ removal and a slower clinical decline in Study 201, and the Phase III study Clarity AD is currently underway.
We will continue to make every effort to deliver a new treatment as soon as possible to Alzheimer's disease patients, their families, and medical professionals.
Our news releases are intended to disclose corporate information and are not intended for the promotion or advertising of prescription pharmaceuticals or investigational products, nor are they intended to provide medical advice.
Please note that the information contained in news releases is current as of the date of publication.